Medicare AWP Reforms Balance Out For Genentech; Avastin Timing Right

The combined impact of changes made to Medicare reimbursement for the non-Hodgkin's lymphoma treatment Rituxan will mean "physicians will not lose money," Genentech Chief Operating Officer Myrtle Potter said